AACR 2023 | Overcoming resistance to KRAS G12C inhibitors in NSCLC

Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, provides an overview of treatment options for patients with non-small cell lung cancer who have progressed on KRAS G12C inhibitors. Despite resistance mechanisms being quite heterogenous, mutation in the Y96 codon is a potential target, and development of a novel inhibitor with different binding patterns to adagrasib is underway. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.